The supplementation of a breakfast by 10 g of guar, pectin, agar or locust bean gum in powder form in 13 maturity onset, non-insulin dependent diabetics failed to decrease significantly the postprandial rise in plasma glucose and insulin seen after a similar meal without the supplement. The values of one hour post-prandial increment in blood glucose seen with guar powder were, for control meal (mean + SEM) 5.8 _+ 0.4 mmol/1, for test, 5.7 + 0.5; with pectin powder, control 6.4 + 0.8 mmol/1, test 5.0 + 1.2 mmol/1; with agar powder, control 7.5 + 1.0, test 7.0 _+ 0.5; with locust bean gum powder, control 5.9 _+ 1.0, test 5.0 +_ 0.7. The equivalent values for one hour insulin (gU/ml, mean + SEM) were, for guar powder, 51 + 21 and 51 + 16; for pectin powder 60 _+ 24 and 63 _+ 17; for agar powder, 27 + 9 and 36 + 11 and, for locust bean gum powder 53 + 26 and 62 + 18. The guar, pectin and locust gum tended to form lumps, and all the substances tested were unpalatable in powder form producing feelings of abdominal discomfort and abnormal fullness. Administering the same quantity of guar or pectin in a well hydrated form (but not premixed with the carbohydrate portion of the food) to the same people under identical conditions did not enhance its effectiveness. Supplementing diets with any of these sources of dietary fibre in either of these forms and in these amounts is unlikely to be beneficial in the management of non-insulin dependent diabetes.
Oral administration of 3-methyl salicylic acid (3MS) to diabetic and non-diabetic patients in modest doses (0.9-1.8 g/day) over several months produced a significant increase in plasma insulin levels, one hour after a glucose load. In 2 diabetic subjects, acute doses had a similar effect.-Improvement in glucose tolerance after chronic administration of 3MS to diabetic patients was inconsistent, and could not be conclusively related to the action of the drug. Although acute doses of 31~{S caused a fall in plasma FFA after 3-6h, chronic treatment gave no predictable change in fasting plasma FFA levels.-Because of side effects, 3MS was not considered suitable for introduction as a therapeutic agent. The results, however, are of academic interest since it is the first demonstration of increased plasma insulin after an oral salicylate. Effet de l'aeide 3-m~thyl salicylique (O-crdsotinique) sur l'insuline plasmatique et la tolerance au glucose chez des sujets diabdtiques et non-diabdtiques R~sumg. L'administration orale d'acide 3-mdthyl salieylique (3MS) k des sujets diab6tiques et non-dia-b6tiques, ~ faibles doses (0.9-1.8 g/jour) pendant plusieurs mois produisait une augmentation signifieative des taux d'insuline plasmatique, une heure apr~s une charge ell glucose. Chez 2 sujets diabdtiques, des doses aigu~s avaient un effct semblable.-Une am6lioration de la tol6ranee au glucose, apr~s administration chronique de 3MS ~ des patients diabdtiques, n'a pas dtg ddcelde et n'a pas pu ~tre relide ~ Faction de la drogue de fa~on coneluante. Bien que des doses aigu~s de 31ViS provoquassent une chute des FFA plasmatiques au bout de 3-6 hs, le traitement chronique ne causait pas de modification prdvisible des taux plasmatiques de FFA k jeun.-A cause des effets secondaires, le 31VIS n'a pas ~tg jugd valable en rant qu'agent thdrapeutique. Les rgsultats cependant, sent d'intdr6t acaddmique, car c'est la premiere d~monstration d'une glgvation de l'insuline plasmatique apr~s administration orMe d'un salicylate. Wirleung der 3-Methyl-Salieyl (O-Kresotin) Sdure auf das Plasmainsulin und die Glucosetoleranz bei Diabetil~ern and Nichtdiabetilcern Die orale Zufuhr yon 3-iYiethyl-Salieyls~iure (31VLS) in relativ niedrigen Dosen (0.9-1.8 g/Tag) an Diabetiker und stoffwechselgesunde Patienten fiber mehrere Monate ffihrte zu einem signifikanten Ansticg der Plasmainsulinspiegel eine Stunde nach Glucosebelastung. Bei 2 Diabetikern riefen akute Gaben einen ~hnliehen Effekt hervet.-Die Besserung der Glucosetoleranz nach chroniseher 3 MS Verabreiehung an Diabetiker war nur vorfibergehend und konnte nicht init Sicherheit auf das 1Viedikament zurfickgeffihrt werden. Obwohl es 3-6 Std nach akuten Gaben yon 31V~S zu einem Abfall der FFS-Konzentrationen im Plasma kam, 15ste die chronisehe Zufuhr keine vorhersagbaren Ver~nderungen.der FFS-Spiegel im Nfichtern-Plasma aus.-Wegen selner Nebenwirkungen erscheint uns die 3i~S zur Einffihrung in die Therapie nicht als geeignet. Die Ergebnisse sind aber yon akademischem Interesse, da mit ihnen zum ersten lVi...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.